Our fund have invested in Advanced Silicon Group (ASG). The Company develops advanced biosensors for biopharmaceutical companies using silicon Nanowire photoelectric technology. The use of nanowire creates a high surface to volume ratio, which makes the sensors more sensitive to low proteins. Furthermore, the sensor allows rapid testing at a low cost. The same test …

Investment in Advanced Silicon Group (ASG)Read More »

Our fund has made a small investment in Conversifi. Conversifi developed a multi-sided platform that connects language learners with native speakers for on-demand conversations over video chat. We first investigated the company in February of this year. Due to the Covid-19 pandemic, we suspended the due diligence in late March. Then back in September, we restarted the …

Investment in Conversifi CompletedRead More »

Our fund have invested in a Life Science Tools company, S2 Genomics. S2 Genomics is a Life Science tools company.  The company has developed SingulatorTM  using patented technology to automates preparation of single cell and nuclei suspensions from solid tissues on cartridges.  The product has just been commercially released.  With many back orders from various industrial clients, the company …

Investment in a Life Science Tools company, S2 GenomicsRead More »

The fund has invested in SharingOS, a company specialized in Micromobility (move within 0-5 miles) market. In the global micromobility market, almost all the vehicles are powered by batteries.  SharingOS has developed a smart battery optimization software platform and distributed smart swappable batteries. The benefits of the swappable battery design by SharingOS allows vehicle operating …

New Investment to SharingOSRead More »

After a few months hibernation due to covid-19 pandemic, your fund managers were back to work in June, starting looking for next startups to invest.  Following two months of analyzing many companies and performing due diligence on a couple of promising ones, we have made investment to CRISP-HP Therapeutics, Inc., a generic engineering company, focusing …

Investment to CRISP-HR Therapeutics, Inc. is CompletedRead More »

Although the fund has temporarily suspended any new investment activities since March, 2020 due to COVID-19 pandemic, your fund managers have been working diligently to manage our existing portfolio, keeping frequent contacts with the companies our fund have invested in.  As expected, the COVID-19 has affected the operations of almost all our invested companies.  However, …

GCAIA Capital May 2020 UpdateRead More »

As 2019 comes to a close, it can be rewarding to reflect on our progress since our angel investing fund was first established. At beginning of the year, we met many startup companies in the DC area and along the East Coast seeking investment to grow their business. We also learned that while there is …

2019 Year End SummaryRead More »